Novel microtubule-targeting agents - the epothilones.
Epothilones are a new class of antimicrotubule agents currently in clinical trials. Their chemical structures are distinct from taxanes and are more amenable to synthetic modification. Six epothilones have been studied in preclinical and clinical trials: patupilone (epothilone B), ixabepilone (BMS247550), BMS 310705, sagopilone (ZK-EPO), KOS-862 (epothilone D), and KOS-1584. In vitro data have shown increased potency in taxane-sensitive and taxane-resistant cancer cell lines. This enhanced cytotoxic effect has been attributed to epothilone being a poor substrate for p-glycoprotein drug resistance protein and having high affinity to the various beta tubulin isoforms. Phase I clinical data have shown different dose-limiting toxicities for each of the epothilones. These effects are drug specific, dose specific, and schedule of administration specific. While diarrhea and myelosuppression are the dose-limiting toxicities for patupilone and BMS 310705, respectively, neurologic toxicity, as seen with taxanes, is the dose-limiting toxicity of ixabepilone, sagopilone, and KOS-862. In an effort to decrease neurologic toxicity, investigators have modified dosing schedules with limited success. Ixabepilone has the most mature clinical results with published phase II and III data, and regulatory approval for clinical use in the treatment of breast cancer. Ixabepilone has also been combined with other anticancer agents and has regulatory approval in combination with capecitabine for heavily treated breast cancer.
Cheng
Kit L
KL
Monter Cancer Center, North Shore - LIJ Health Systems, Lake Success, New York, USA.
Bradley
Thomas
T
Budman
Daniel R
DR
Clin Cancer Res. 2005 Sep 1;11(17):6233-9
16144926
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2904-9
10688884
Cancer Res. 2005 Oct 1;65(19):9021-8
16204076
Lancet Oncol. 2004 Mar;5(3):158-64
15003198
Curr Cancer Drug Targets. 2007 Dec;7(8):713-29
18220532
J Clin Oncol. 1999 Jun;17(6):1786-93
10561216
Cancer. 2007 Aug 1;110(3):556-63
17577218
Eur J Cancer. 2008 Mar;44(5):674-82
18308561
Cancer Res. 2002 Apr 1;62(7):1935-8
11929805
Clin Cancer Res. 2007 Dec 15;13(24):7480-6
18094432
Ann Oncol. 2007 Jul;18 Suppl 5:v9-15
17656562
Science. 2004 Aug 6;305(5685):866-9
15297674
Angew Chem Int Ed Engl. 2006 Dec 4;45(47):7942-8
17006870
Cancer Res. 2008 Jul 1;68(13):5380-9
18593940
J Clin Oncol. 2007 Aug 10;25(23):3407-14
17606974
Clin Cancer Res. 2005 Sep 1;11(17):6359-69
16144941
Cancer Chemother Pharmacol. 2008 Dec;63(1):157-66
18347795
Mol Cancer Ther. 2006 Sep;5(9):2348-57
16985069
Clin Cancer Res. 2007 Jul 15;13(14):4178-84
17634546
Oncology. 2006;71(3-4):292-6
17657173
J Clin Oncol. 2005 Mar 1;23(7):1439-46
15735119
Ann Oncol. 2004 Jun;15(6):928-32
15151950
J Clin Oncol. 2005 Dec 1;23(34):8724-9
16314632
Cancer. 2007 Aug 15;110(4):759-63
17594721
J Clin Oncol. 2007 Aug 10;25(23):3421-7
17606971
J Clin Oncol. 2005 May 1;23(13):3069-73
15860865
J Clin Oncol. 2007 Aug 10;25(23):3448-55
17606973
Invest New Drugs. 2007 Dec;25(6):565-70
17618407
Clin Cancer Res. 2008 Mar 15;14(6):1618-24
18347162
J Biol Chem. 1997 Jan 24;272(4):2534-41
8999970
Curr Pharm Des. 2005;11(13):1595-613
15892665
Cancer Sci. 2006 Sep;97(9):813-20
16805818
Clin Cancer Res. 2004 Feb 15;10(4):1289-98
14977827
J Biol Chem. 2005 Apr 1;280(13):12902-7
15695826
Cancer. 2013 May 1;119(9):1683-9
23310949
J Clin Oncol. 2007 Aug 10;25(23):3415-20
17606972
Cancer Res. 2008 Jul 1;68(13):5301-8
18593931
Mol Cancer Ther. 2005 Dec;4(12):2001-7
16373715
J Clin Oncol. 2003 May 1;21(9):1866-73
12721265
J Clin Oncol. 2005 Apr 20;23(12):2726-34
15837987
Clin Cancer Res. 2007 May 15;13(10):2849-54
17504982
Clin Cancer Res. 2008 May 1;14(9):2701-9
18451235
J Antibiot (Tokyo). 1996 Jun;49(6):560-3
8698639
Cancer Invest. 2005;23(5):479-80
16193646
Curr Drug Targets. 2000 Jul;1(1):85-99
11475537
J Neurooncol. 2009 Oct;95(1):61-64
19381446
Cancer Res. 1995 Jun 1;55(11):2325-33
7757983
J Clin Oncol. 2004 May 15;22(10):2015-25
15143095
Prog Drug Res. 2008;66:273, 275-334
18416309
Ann Oncol. 2007 Dec;18 Suppl 12:xii15-20
18083698
Ann Oncol. 2007 Jan;18(1):190-195
17018704
J Clin Oncol. 2007 Mar 20;25(9):1082-8
17261851
J Clin Oncol. 2005 Dec 20;23(36):9120-9
16301595
Cancer Chemother Pharmacol. 2008 Apr;61(5):751-8
17594093
Ann Oncol. 2007 Sep;18(9):1548-53
17761711
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15798-802
9861050
Cancer Invest. 2005;23(3):264-73
15948296
J Clin Oncol. 2008 May 1;26(13):2223
18445853
Ann Oncol. 2008 May;19(5):977-83
18296423
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8
16203787
Invest New Drugs. 2006 Nov;24(6):515-20
16699973
Cancer. 2005 May 1;103(9):1932-8
15800893
FEBS J. 2006 Jul;273(14):3301-10
16803461
Breast Cancer Res Treat. 2010 Feb;119(3):663-71
20012354
Acc Chem Res. 2008 Jan;41(1):21-31
18159935
Invest New Drugs. 2006 Sep;24(5):441-6
16586011
Anticancer Res. 2008 Mar-Apr;28(2B):1161-7
18505052
Support Care Cancer. 2003 Mar;11(3):144-7
12618923
Invest New Drugs. 2007 Oct;25(5):487-90
17520176
Cancer Biol Ther. 2007 Apr;6(4):490-3
17457044
Invest New Drugs. 2007 Aug;25(4):327-34
17347871
J Clin Oncol. 2007 Nov 20;25(33):5210-7
17968020
Mol Pharmacol. 2008 Oct;74(4):1072-83
18593821
Clin Cancer Res. 2001 May;7(5):1429-37
11350914
J Clin Oncol. 2007 Aug 10;25(23):3399-406
17606975
Prog Med Chem. 2004;42:171-205
15003721
Nature. 1997 May 15;387(6630):268-72
9153390
Cell Cycle. 2008 Feb 15;7(4):477-83
18235240
Clin Cancer Res. 2008 Jul 15;14(14):4378-84
18628451
Oncologist. 2007 Mar;12(3):271-80
17405891